Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.

NCT ID: NCT06145048

Last Updated: 2025-03-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 89 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-10-05
• Study Completion Date: 2025-02-20

Brief Summary

This is a Phase 2, multi-center, open-label study to evaluate the safety and efficacy of VGT-309, a tumor-targeted, activatable fluorescent imaging agent, in subjects undergoing surgery for proven or suspected cancer in the lung. Approximately 100 subjects will be enrolled to ensure at least 86 subjects are evaluable with the option to expand enrollment by protocol amendment if deemed necessary by the DSC to meet primary and/or secondary objectives.

Detailed Description

This is a Phase 2, multi-center, open-label study to evaluate the safety and efficacy of VGT-309, a tumor-targeted, activatable fluorescent imaging agent, in subjects undergoing surgery for proven or suspected cancer in the lung. Approximately 100 subjects will be enrolled to ensure at least 86 subjects are evaluable with the option to expand enrollment by protocol amendment if deemed necessary by the DSC to meet primary and/or secondary objectives.

Following agreement with and signing of the informed consent, subjects will undergo screening measurements for the study within 4 weeks prior to the anticipated dosing:

1. Medical, surgical and medication history.

2. Complete physical exam, including vital signs and height

3. Weight (needed for dose calculation)

4. Chemistry, hematology, coagulation and urinalysis with microscopy clinical laboratory studies.

5. 12-lead ECG.

6. Serum pregnancy test for females of child-bearing potential.

After meeting all enrollment criteria, each subject will receive 0.32 mg/kg VGT-309 by IV administration 12-36 hours prior to surgery (refer to section VGT-309 Dosing, below). Subjects will be observed for 1 hour after dosing is completed and asked about possible treatment emergent adverse events.

Subjects will undergo surgical resection within 12-36 hours after completion of VGT-309 dosing. Measurements of efficacy will be taken during surgery and during the pathological examination of all surgical specimens. (Refer to Efficacy Endpoints and Efficacy Assessments sections).

Following surgery, subjects will be monitored for safety during their hospitalization. Between 7 to 14 and 25 to 35 days after surgery, the subjects will return to the clinic or have a telehealth visit for final safety assessments. At the last visit, if there are no adverse events requiring further follow up, subjects will then be released from the study.

Conditions

Lung Cancer; Lung Metastases

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

0.32 mg/kg VGT-309

0.32 mg/kg VGT-309 given over 15-20 minutes by syringe pump

Group Type: EXPERIMENTAL

VGT-309

Intervention Type: DRUG

Intravenous drug to be given over 15-20 minutes by syringe pump.

Interventions

VGT-309

Intravenous drug to be given over 15-20 minutes by syringe pump.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Be willing and able to sign the informed consent and comply with study procedures.

2. Be at least 18 years of age.

3. Meet the following conditions:

Female participants must be of non-childbearing potential, or, If of childbearing potential, be non-pregnant or non-lactating and agree to use highly effective contraception from screening through Day 30 after treatment.

Male participants, if not surgically sterilized, and if engaging in sexual intercourse with a female partner of childbearing potential, must be willing to use highly effective contraception from screening through 30 days after treatment and agree not to donate semen during this waiting period.

Highly effective contraception involves the use of a condom for the male, plus one of the following for the female:

Oral, injectable, implantable, intravaginal, or transdermal hormonal contraceptives, or Intrauterine device or intrauterine hormone-releasing system NOTE: Subjects who abstain from heterosexual intercourse as their usual and preferred lifestyle, will not be required to use contraception as described above. They are required to maintain abstinence from screening through Day 30 after treatment.

Note: Subjects in a same sex relationship, must use a barrier form of contraception (e.g., condom, diaphragm) to protect against the transfer of the study drug in any bodily fluids.

4. Have a lung nodule or mass that might be considered primary lung cancer or lung metastases whether or not it is biopsy-proven before surgery.

5. Be scheduled to undergo standard of care surgical resection for a lung nodule or mass with diagnostic and/or curative intent

6. Have acceptable kidney and liver functions at study entry as evidenced by:

ALT/AST < 1.5 times the upper limit of normal Calculated Creatinine Clearance (CrCl) ≥ 50 ml/min Total bilirubin < 1.5 times the upper limit of normal Have an ECOG score of 0-2. Meet all standard of care surgical and general anesthesia requirements. 7) Have not participated in an interventional clinical trial within the last 30 days.

-

Exclusion Criteria

1. Not a candidate for standard of care surgery based on opinion of the surgeon, anesthesiologist, or other consulting physician.

2. Have a known allergy or reaction to ICG, other radiographic contrast agent, or any component of VGT-309.

3. Have congenital long QT syndrome or QTcF > 470ms by history or at Screening ECG.

4. Prisoners, institutionalized individuals, or are unable to consent for themselves.

5. Have any other co-morbidity or habit that the Investigator believes will interfere with their ability to comply with and complete the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Vergent Bioscience, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Curtis Scribner, MD

Role: STUDY_DIRECTOR

Vergent Bioscience

Locations

City of Hope National Medical Center

Duarte, California, United States

Orlando Health Cancer Institute

Orlando, Florida, United States

Mayo Clinic

Rochester, Minnesota, United States

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

University of Texas MD Anderson Cancer Center

Houston, Texas, United States

St. Vincent's Hospital

Melbourne, Victoria, Australia

Countries

United States; Australia

Other Identifiers

VGT-309-2B-2023

Identifier Type: -

Identifier Source: org_study_id